564 related articles for article (PubMed ID: 25510900)
1. Calcitriol and its analogues enhance the antiproliferative activity of gefitinib in breast cancer cells.
Segovia-Mendoza M; Díaz L; González-González ME; Martínez-Reza I; García-Quiroz J; Prado-Garcia H; Ibarra-Sánchez MJ; Esparza-López J; Larrea F; García-Becerra R
J Steroid Biochem Mol Biol; 2015 Apr; 148():122-31. PubMed ID: 25510900
[TBL] [Abstract][Full Text] [Related]
2. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY
Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280
[TBL] [Abstract][Full Text] [Related]
3. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
4. Tumor inhibitory effect of gefitinib (ZD1839, Iressa) and taxane combination therapy in EGFR-overexpressing breast cancer cell lines (MCF7/ADR, MDA-MB-231).
Takabatake D; Fujita T; Shien T; Kawasaki K; Taira N; Yoshitomi S; Takahashi H; Ishibe Y; Ogasawara Y; Doihara H
Int J Cancer; 2007 Jan; 120(1):181-8. PubMed ID: 17036319
[TBL] [Abstract][Full Text] [Related]
5. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
[TBL] [Abstract][Full Text] [Related]
6. Treatment with cucurbitacin B alone and in combination with gefitinib induces cell cycle inhibition and apoptosis via EGFR and JAK/STAT pathway in human colorectal cancer cell lines.
Yar Saglam AS; Alp E; Elmazoglu Z; Menevse S
Hum Exp Toxicol; 2016 May; 35(5):526-43. PubMed ID: 26183715
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells.
Camirand A; Zakikhani M; Young F; Pollak M
Breast Cancer Res; 2005; 7(4):R570-9. PubMed ID: 15987464
[TBL] [Abstract][Full Text] [Related]
8. FoxO proteins' nuclear retention and BH3-only protein Bim induction evoke mitochondrial dysfunction-mediated apoptosis in berberine-treated HepG2 cells.
Shukla S; Rizvi F; Raisuddin S; Kakkar P
Free Radic Biol Med; 2014 Nov; 76():185-99. PubMed ID: 25128467
[TBL] [Abstract][Full Text] [Related]
9. BIM induction of apoptosis triggered by EGFR-sensitive and resistance cell lines of non-small-cell lung cancer.
Li Z; Zhou S; Zhang L; Su C; Hang J; Zhao Y; Su B; Zhou C
Med Oncol; 2011 Jun; 28(2):572-7. PubMed ID: 20237869
[TBL] [Abstract][Full Text] [Related]
10. Effects of pemetrexed, gefitinib, and their combination on human colorectal cancer cells.
Zhang G; Xie X; Liu T; Yang J; Jiao S
Cancer Chemother Pharmacol; 2013 Oct; 72(4):767-75. PubMed ID: 23959460
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu.
Piechocki MP; Yoo GH; Dibbley SK; Lonardo F
Cancer Res; 2007 Jul; 67(14):6825-43. PubMed ID: 17638894
[TBL] [Abstract][Full Text] [Related]
12. PANC-1 pancreatic cancer cell growth inhibited by cucurmosin alone and in combination with an epidermal growth factor receptor-targeted drug.
Wang C; Yang A; Zhang B; Yin Q; Huang H; Chen M; Xie J
Pancreas; 2014 Mar; 43(2):291-7. PubMed ID: 24518510
[TBL] [Abstract][Full Text] [Related]
13. Enediyne lidamycin enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib, in epidermoid carcinoma A431 cells and lung carcinoma H460 cells.
Liu H; Li L; Li XQ; Liu XJ; Zhen YS
Anticancer Drugs; 2009 Jan; 20(1):41-9. PubMed ID: 19342999
[TBL] [Abstract][Full Text] [Related]
14. Novel combination therapy against metastatic and androgen-independent prostate cancer by using gefitinib, tamoxifen and etoposide.
Mimeault M; Venkatraman G; Johansson SL; Moore E; Henichart JP; Depreux P; Lin MF; Batra SK
Int J Cancer; 2007 Jan; 120(1):160-9. PubMed ID: 17013895
[TBL] [Abstract][Full Text] [Related]
15. Role of survivin in EGFR inhibitor-induced apoptosis in non-small cell lung cancers positive for EGFR mutations.
Okamoto K; Okamoto I; Okamoto W; Tanaka K; Takezawa K; Kuwata K; Yamaguchi H; Nishio K; Nakagawa K
Cancer Res; 2010 Dec; 70(24):10402-10. PubMed ID: 21159653
[TBL] [Abstract][Full Text] [Related]
16. Dual inhibition of MEK1/2 and EGFR synergistically induces caspase-3-dependent apoptosis in EGFR inhibitor-resistant lung cancer cells via BIM upregulation.
Song JY; Kim CS; Lee JH; Jang SJ; Lee SW; Hwang JJ; Lim C; Lee G; Seo J; Cho SY; Choi J
Invest New Drugs; 2013 Dec; 31(6):1458-65. PubMed ID: 24068620
[TBL] [Abstract][Full Text] [Related]
17. HES1-mediated inhibition of Notch1 signaling by a Gemini vitamin D analog leads to decreased CD44(+)/CD24(-/low) tumor-initiating subpopulation in basal-like breast cancer.
So JY; Wahler J; Das Gupta S; Salerno DM; Maehr H; Uskokovic M; Suh N
J Steroid Biochem Mol Biol; 2015 Apr; 148():111-21. PubMed ID: 25541438
[TBL] [Abstract][Full Text] [Related]
18. Influence of gefitinib and erlotinib on apoptosis and c-MYC expression in H23 lung cancer cells.
Suenaga M; Yamamoto M; Tabata S; Itakura S; Miyata M; Hamasaki S; Furukawa T
Anticancer Res; 2013 Apr; 33(4):1547-54. PubMed ID: 23564796
[TBL] [Abstract][Full Text] [Related]
19. Sequence-dependent antiproliferative effects of gefitinib and docetaxel on non-small cell lung cancer (NSCLC) cells and the possible mechanism.
Chen B; Zheng J; Zeng Y; Li B; Xie B; Zheng J; Zhou J; Zhang W
PLoS One; 2014; 9(12):e114074. PubMed ID: 25474307
[TBL] [Abstract][Full Text] [Related]
20. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
